From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Lenvatinib (N, %)
Sorafenib (N, %)
p-value
CR
2 (4.5%)
3 (3.4%)
PR
6 (13.6%)
1 (1.1%)
SD
26 (59.1%)
38 (43.2%)
PD
10 (22.7%)
44 (50.0%)
Not assessed
0 (0%)
2 (2.3%)
ORR
18.2%
4.5%
0.020
DCR
77.3%
47.7%
0.001